Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LGMN | Q99538 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31162190 | 0.87 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL30278792 | 0.87 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL31162392 | 0.87 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL31162202 | 0.84 | MEN1 (0.41) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL31162388 | 0.84 | PPM1B (0.41) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL31162271 | 0.84 | MEN1 (0.41) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL31162511 | 0.84 | MEN1 (0.41) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL30545997 | 0.84 | MEN1 (0.41) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL31162260 | 0.84 | MEN1 (0.41) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL30747367 | 0.84 | MEN1 (0.41) | MEN1KMT2AMAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| CN-119486992-A | PI3K alpha inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | MEN1 3701/4885KMT2A 2974/4885MAPT 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.